INTRODUCTION
============

The proximal humerus is a common location for both primary and metastatic bone tumors. Numerous reconstruction and stabilization options after surgical management exist including allograft, alloprosthetic composite (APC), megaprosthesis, and more recently, reverse shoulder arthroplasty (RSA). The main goals of reconstruction are to restore function and limit complications. Patient activity, tumor characteristics, and anatomic involvement are important factors to consider when selecting the optimal reconstruction.

There is no consensus on the ideal method of reconstruction. There are numerous case series, but there is a lack of high-level comparative evidence between different options. The purpose of this study was to extensively review the existing literature.

METHODS
=======

A systematic review of English-language literature was performed of PubMed and Medline/Ovid electronic medical databases with a focus on surgical reconstructive options for resection of proximal humerus bone lesions. All articles published as of September 1, 2015 were subject to review (Fig. **[1](#F1){ref-type="fig"}**). Articles were excluded if they were cases series of less than 5 total patients or if scapular resection was performed. Fifty articles were included for analysis (Table **[1](#T1){ref-type="table"}**).

Each study was reviewed and pertinent data was recorded including patient demographics, length of follow-up, primary *versus* metastatic tumor, range of motion, rate of reoperation, infectious complications, and mechanical complications (dislocation, shoulder instability, peri-prosthetic fracture, prosthetic loosening). Post-operative functional scores were recorded when available. Data was sorted by reconstruction method. Complication rates and functional scores were calculated (Table **[2](#T2){ref-type="table"}**).

RESULTS
=======

A total of 50 articles and 1227 patients were included for analysis. The mean age of patients in the available data was 38.7 years of age with a mean post-surgical follow-up of 70.5 months. There were 30 studies qualified as Level IV evidence, 17 as Level III, and 3 studies as Level II evidence \[[@R1]\].

The method of reconstruction with the most published evidence was megaprosthesis. Hemiarthroplasty had relatively few articles dedicated to its use in tumor reconstruction, but likely is more widely used for humeral head lesions, particularly in metastatic scenarios. Reverse shoulder arthroplasty is a relatively newer option and has less long-term evidence than megaprosthesis or allograft reconstruction.

Mechanical complications were relatively high for all arthroplasty options ranging between 20-29%. Both allograft and autograft arthrodesis had relatively low mechanical complications (17-21%). Osteoarticular allografts had among the highest rate of mechanical complications (46%) and reoperation (34%) (Table **[3](#T3){ref-type="table"}**). Of the arthroplasty options, megaprosthesis had the lowest reoperation rate (10%). Infection was relatively low for both megaprosthesis (4%) and hemiarthroplasty (0%). Reverse arthroplasty had a greater than double higher infection rate (9%).

Vascularized fibula has a relatively high number of published cases. It has a low rate of infection (0%) and few mechanical complications (17%), but similar levels of reoperation (14%) to other methods of reconstruction. Claviculo Pro Humeri is a rare procedure and has very high rates of mechanical complications (47%) and infection (21%).

A variety of scores were used to assess postoperative function with the Musculoskeletal Tumor Society Score being the most consistently reported \[[@R2]\]. The functional outcomes were similar amongst different reconstruction options, ranging from 66% to 83%. For active range of motion, patients were generally only able obtain abduction between 45° to 90°. With resection of the rotator cuff, deltoid muscle or axillary nerve, function and stability were significantly compromised. The effect of glenoid resection varied amongst studies. If the deltoid and axillary nerve were preserved, the ability to regain active forward flexion and abduction was significantly better with RSA. To achieve external rotation with RSA, muscle transfer was occasionally necessary to compensate for a deficient posterior rotator cuff. Pain scores were not specifically reported in the majority of studies.

DISCUSSION
==========

Given the collection of available data from over 50 articles and 1200 patients, favorable results in most situations can be expected albeit with limited functional outcomes. Patients with extensive tumor involvement in the proximal humerus often require creative reconstruction solutions, leading to wide variability between studies and even within one institution. It should be noted that although the functional scores between reconstruction methods are similar, there is a wide spectrum of post-resection/pre-reconstruction bone and soft tissue compromise. This phenomenon can be interpreted that either a modest functional outcome is usually achievable regardless of reconstruction method or that with increasingly complex situations, increasingly complex reconstructions can achieve similar functional levels as less complex situations. If one believes the more nihilistic former approach, then it makes sense to pursue the simplest option with the least risk of complications. If one believes the latter, then reconstruction should be tailored to the specific anatomic scenario with some consideration to the patient's physical demands and tolerance for complications. Because numerous reconstructive options are available, adequate margins should always be endeavored based on the clinical situation in order to minimize the risk of local recurrence, particularly for more aggressive phenotypes. For patients with limited estimated lifespan such as in the setting of metastatic disease and in situations which postoperative radiation and chemotherapy are required, reconstructive options that allow early weight bearing and use of the shoulder and that do not rely on bone healing such as prosthetic replacement are preferred.

Hemiarthroplasty is useful for minor bone loss situations such as primary malignant tumors limited to the humeral head and metastatic lesions not amenable to intramedullary nailing. Because shoulder function with hemiarthroplasty is dependent on the integrity of the rotator cuff and greater tuberosity which is often compromised by tumor involvement it is not surprising that functional scores are limited. Although the mechanical complication rate was relatively high in this systematic review, it can be partially attributed to the frequency of subluxation requiring soft tissue reconstruction \[[@R3], [@R4]\]. Glenoid wear can be expected in young patients with hemiarthroplasty \[[@R5]\], but most oncological patients requiring hemiarthroplasty are \>50 years old. Conversion of a painful hemiarthroplasty to total shoulder arthroplasty lead to a high rate of unsatisfactory results \[[@R6]\].

Current revision long-stem humeral stems allow surgeons to cement a hemiarthroplasty slightly proud and compensate for a limited bone defect of the medial calcar. For more extensive bone loss, megaprostheses are a relatively simple solution. This study group of over 700 patients includes a variety of prostheses and pre-reconstruction bone deficits. Consequently, there is a wide spectrum of functional MSTS scores in this group (55-82%). Active range of motion after megaprosthesis reconstruction is largely dependent on healing of the tendon-prosthetic interface, which is unpredictable at best. Nevertheless, the overall complication rates for megaprostheses were relatively favorable with limited infections (4%), revision surgery (10%) and mechanical complications (17%). No study had an infection rate greater than 10% and multiple studies reported 0% \[[@R7]-[@R10]\]. Additionally, mechanical complications were commonly treated conservatively including subluxation, dislocation, prosthetic loosening, and periprosthetic fracture.

The clinical context for RSA is unclear. Situations in which sacrifice of the rotator cuff is necessary but preservation of the deltoid insertion and axillary nerve is possible, RSA may be considered. For non-oncological situations, RSA is conventionally reserved for older, lower-demand patients because longevity of modern implants are unknown and there is risk of a 'tired deltoid' at ten years \[[@R11]\]. It is also often reported to have a higher complication rate than other arthroplasty options \[[@R12]\]. For oncologic patients, an older, lower-demand demographic is typically an indication for less functionally aggressive options such as megaprosthesis or hemiarthroplasty. Many elderly oncology patients require their upper extremities to push oneself out of a chair or to support themselves due to lower extremity weakness. This motion (extension, adduction, external rotation, axial loading) predisposes them to dislocation of RSA. Additionally, the higher infection rate (9%) may delay postoperative chemotherapy or radiation therapy. For younger individuals, they will likely encounter many or more of the same complications with RSA as young non-oncologic patients.

For high demand, younger patients requiring resection distal to the deltoid insertion, an alloprosthetic composite (APC) may be advantageous to allow for tendinous reattachment to preserved allograft tendon insertions. However, APC is a technically more challenging procedure and has a much higher rate of complications requiring revision than megaprosthesis including fracture and nonunion. The functional results for APC are similar to other reconstructive options and so the risks and benefits need to be carefully weighed.

Osteoarticular allografts are less frequently used since the advent of improved prosthetic options. With a high rate of complications requiring reoperation, numerous fractures and a lengthy time to union, there are no highly compelling reasons to choose osteoarticular bulk allografts in oncologic situations. Several articles report rates of mechanical failure in over 60% of cases \[[@R13]-[@R16]\]. Autologous vascularized fibular grafts, with or without allograft supplementation, on the other hand, have superior results and fewer complications. If early fracture is avoided, the graft has the ability to hypertrophy, to avoid infection and unite with the native bone to a greater extent than allograft or non-vascularized autograft. Claviculo-Pro-Humeri (CPH) similarly provides a biologic reconstruction option as the ipsilateral clavicle functions as a rotational bone flap to replace the resected proximal humerus. Its principle advantage is the construct's inherent proximal stability through the acromioclavicular ligaments. It reportedly has the best functional outcomes of all reconstruction options, but is limited to pediatric patients and may often require reoperation for nonunion \[[@R17]\].

Arthrodesis is traditionally limited to young adult patients expected to subject their shoulders to high levels of physical stress and to patients undergoing salvage of a failed limb-sparing reconstruction. Both allograft and autograft options appear to yield similar rates of mechanical complications and infection. Remarkably, functional scores are also similar to other motion-preserving reconstructions and are similar between primary or secondary arthrodesis \[[@R18]\]. Patients are able to compensate through preserved scapulothoracic and elbow motion.

In conclusion, hemiarthroplasty is the simplest option for minimal bone loss. For loss of the rotator cuff and deltoid insertion/axillary nerve, RSA and APC, respectively, provide potential for greater function, but have higher complications than megaprosthesis and the risks and benefits need to be carefully considered. Autograft arthrodesis, vascularized fibula, and CPH are effective in certain situations.
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###### 

Summary of data from literature review on proximal humeral reconstruction.

  Authors                                        Type of Fixation           \"n\"   Mean Follow-up (mo)   Mean age (yrs)   Tumor Type (% primary lesions)   Tumor-specific Mortality
  ---------------------------------------------- -------------------------- ------- --------------------- ---------------- -------------------------------- --------------------------
  Salzer M *et al.* (1979) \[[@R19]\]            Megaprosthesis             27      27.4                                   58%                              37%
  Campanacci M *et al.* (1982) \[[@R20]\]        Megaprosthesis             13                                             85%                              31%
  Bos G *et al.* (1987) \[[@R10]\]               Megaprosthesis             18      68.4                                   100%                             11%
  Ross AC *et al.* (1987) \[[@R21]\]             Megaprosthesis             19      132                                    89%                              11%
  Capanna R *et al.* (1988) \[[@R22]\]           Megaprosthesis             19      18.2                  51               0%                               63%
  Gebhardt MC *et al.* (1990) \[[@R23]\]         Osteoarticular allograft   23      63.6                  33               96%                              13%
  Jensen RL *et al.* (1995) \[[@R24]\]           *Overall*                  19      39                                     100%                             23%
  APC                                            4                                  43                    100%             0%                               
  Hemiarthroplasty                               15                                 38                    100%             27%                              
  O\'Connor MI *et al.* (1996) \[[@R13]\]        *Overall*                  20                                             100%                             
  Osteoarticular allograft                       8                                                                                                          
  Megaprosthesis                                 11                                                                                                         
  Allograft arthrodesis                          1                                                                                                          
  Freedman *et al.* (1997) \[[@R25]\]            Megaprosthesis             5                                              20%                              60%
  Probyn LJ *et al.* (1998) \[[@R26]\]           *Overall*                  21                                                                              
  Osteoarticular allograft                       11                         45.6    34                    100%             0%                               
  Allograft arthrodesis                          7                                                                                                          
  Autograft arthrodesis                          3                                                                                                          
  Asavamongkolkul A *et al.* (1999) \[[@R27]\]   Megaprosthesis             59      90                    33               90%                              46%
  Fabroni RH *et al.* (1999) \[[@R8]\]           Megaprosthesis             8       165                   22               100%                             
  Getty PJ *et al.* (1999) \[[@R14]\]            Osteoarticular allograft   16      34                                                                      13%
  Wada T *et al.* (1999) \[[@R28]\]              Vascularized fibula        8       70                    27               100%                             13%
  Shin KH *et al.* (2000) \[[@R29]\]             *Overall*                  7       35.6                  23.4                                              18%
  Megaprosthesis                                 1                                                                                                          
  APC                                            6                                                                                                          
  Gebhart M *et al.* (2001)\[[@R7]\]             Megaprosthesis             16                                                                              
  Rodl W *et al.* (2002)\[[@R30]\]               *Overall*                  45                            27               100%                             36%
  Osteoarticular allograft                       11                                 20                    100%                                              
  CPH                                            15                                 18                    100%                                              
  Megaprosthesis                                 19                                 37                    100%                                              
  De Wilde L *et al.* (2003) \[[@R31]\]          RSA                        13      36                    48.8                                              
  Ippolito V *et al.* (2003) \[[@R32]\]          Megaprosthesis             20                            68               0%                               
  Kumar D *et al.* (2003) \[[@R33]\]             Megaprosthesis             100     108                   34               83%                              44%
  DeGroot H *et al.* (2004) \[[@R16]\]           Osteoarticular allograft   32                            30                                                6%
  Zeegen EN *et al.* (2004) \[[@R34]\]           Megaprosthesis             15                            49                                                
  Fuchs B *et al.* (2005) \[[@R18]\]             *Overall*                  21      231                   26                                                0%
  Allgraft arthrodesis                           12                         123.6   26                                     0%                               
  Autograft arthrodesis                          9                          157     27                                     0%                               
  Mayilvahanan N *et al.* (2006) \[[@R35]\]      Megaprosthesis             57      66                    27.9             91%                              11%
  Black AW *et al.* (2007) \[[@R36]\]            APC                        6       55                                     83%                              
  Kitagawa Y *et al.* (2007) \[[@R4]\]           *Overall*                  6       21                    54               100%                             32%
  Hemiarthroplasty                               5                          38      55                    100%                                              
  Allograft arthrodesis                          1                                  51                    100%                                              
  Sharma S *et al.* (2007) \[[@R9]\]             Megaprosthesis             21      47.9                                                                    
  El-Sherbiny M *et al.* (2008) \[[@R37]\]       *Overall*                  32                            21               97%                              6%
  Megaprosthesis,                                13                                                                                                         
  Vascularized fibula                            11                                                                                                         
  Pedicled lateral scapular crest graft          8                                                                                                          
  Scotti C *et al.* (2008) \[[@R38]\]            Megaprosthesis             40                            67               0%                               
  Cannon CP *et al.* (2009) \[[@R39]\]           Megaprosthesis             83      30                    55                                                
  Moran M *et al.* (2009) \[[@R3]\]              Hemiarthroplasty           11      69                    21.5             100%                             18%
  Potter B *et al.* (2009) \[[@R15]\]            *Overall*                  49      113                   48.5             51%                              51%
  Osteoarticular allograft                       17                                 36.5                                                                    
  APC                                            16                                 56.3                                                                    
  Megaprosthesis                                 16                                 53.6                                                                    
  Piccioli A *et al.* (2010) \[[@R40]\]          Megaprosthesis             30                                             0%                               
  Raiss P *et al.* (2010) \[[@R41]\]             Megaprosthesis             39      38                                     23%                              23%
  Wang Z *et al.* (2010) \[[@R42]\]              *Overall*                  25      48                    32               88%                              8%
  Osteoarticular allograft                       12                                                                                                         
  APC                                            7                                                                                                          
  Megaprosthesis                                 6                                                                                                          
  Yang Q *et al.* (2010) \[[@R43]\]              *Overall*                  12                                             100%                             
  Osteoarticular allograft                       3                                                                                                          
  Megaprosthesis                                 7                                                                                                          
  Vascularized fibula                            2                                                                                                          
  De Wilde L *et al.* (2011) \[[@R44]\]          RSA                        14      92.4                  45.1             71%                              29%
  Griffiths D *et al.* (2011) \[[@R45]\]         Megaprosthesis             58      71                    46               59%                              28%
  Ruggieri P *et al.* (2011) \[[@R46]\]          APC                        14      25                    35               100%                             0%
  Bilgin SS (2012) \[[@R47]\]                    Autograft arthrodesis      6       60                                                                      
  Hartigan DE *et al.* (2012) \[[@R48]\]         APC                        27      76.8                  43.8             85%                              11%
  Li J *et al.* (2012) \[[@R49]\]                Vascularized fibula        6       19.1                  15.8             100%                             0%
  Aponte-Tinao LA *et al.* (2013) \[[@R50]\]     *Overall*                  37      60                    32                                                
  Osteoarticular allograft                                                                                                                                  
  APC                                                                                                                                                       
  Kaa AK *et al.* (2013) \[[@R51]\]              RSA                        16      46                    41.5             50%                              31%
  van de Sande *et al.* (2013) \[[@R52]\]        *Overall*                  37      120                   44.8             89%                              27%
  Osteoarticular allograft                       13                                                                        46%                              
  APC                                            10                                                                        20%                              
  Megaprosthesis                                 14                                                                        14%                              
  Liu T *et al.* (2014) \[[@R53]\]               *Overall*                  41      57.7                  30.6             100%                             
  Megaprosthesis                                 25                                                                        32%                              
  Vascularized fibula                            16                                                                        38%                              
  Bonnevialle N *et al.* (2015) \[[@R54]\]       RSA                        10      42                    55               60%                              20%
  Calvert GT *et al.* (2015) \[[@R17]\]          CPH                        4                             5.9                                               
  Pruksakorn D *et al.* (2015) \[[@R55]\]        Megaprosthesis             13      14.3                                   0%                               15%
  Streitbuerger A *et al.* (2015) \[[@R56]\]     Megaprosthesis             18      33.6                  42               66%                              11%

RSA: Reverse Shoulder Arthroplasty, APC: Alloprosthetic Composite, CPH: Claviculo Pro Humeri

###### 

Summary of reconstruction techniques and complications.

  Treatment Method                 Number of Articles   \'n\'   Average Age (yrs)   Infection Rate (%)   Mechanical Failure (%)   Reoperation (%)   MSTS (%)
  -------------------------------- -------------------- ------- ------------------- -------------------- ------------------------ ----------------- ----------
  Reverse shoulder arthroplasty    4                    53      47                  9%                   23%                      17%               74%
  Hemiarthroplasty                 4                    31      35                  0%                   29%                      26%               66%
  Megaprosthesis                   30                   761     45                  4%                   17%                      10%               72%
  Alloprosthetic composite         9                    106     45                  6%                   30%                      26%               73%
  Osteoarticular allograft         11                   167     31                  7%                   46%                      34%               74%
  Vascularized fibula              5                    43      22                  0%                   17%                      14%               73%
  Allograft arthrodesis            4                    19      26                  12%                  21%                      32%               74%
  Autograft arthrodesis            3                    20      25                  7%                   17%                      11%               76%
  CPH                              2                    19      18                  21%                  47%                      47%               83%
  Pedicled lateral scapula graft   1                    8                                                25%                      25%               68%
  Total                            50                   1227                                                                                        

###### 

Summary of mechanical complications.

                                           Mechanical Complication (% of total)   Re-operation (% of total)
  ---------------------------------------- -------------------------------------- ---------------------------
  Instability (subluxation, dislocation)   52.0                                   24.1
  Aseptic loosening                        10.5                                   16.1
  Non-union                                23.0                                   12.6
  Fracture                                 9.9                                    26.4
  Infection                                                                       17.8
  Other                                    4.6                                    2.9
